fig5
![MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression](https://image.oaes.cc/110f735f-64b9-49ee-9793-5d4b2035bc3f/3433.fig.5.jpg)
Figure 5. ErbB family signaling bypasses JAK activation in MMTV-Neu cells. A-D: immunoblot analysis of MMTV-Neu (A), E0771 (B), EMT6 (C), and 4T1 (D) cells treated with or without trametinib (50 nM; MEKi) along with Erlotinib (0.5 µM) or Lapatinib (0.1 µM) for 48 h prior to lysis. MEKi: MEK inhibition